|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Parallel Trade Outlook: Challenges To Pharmaceutical Companies Across Europe And The US
Business Insights, Feb 2004, Pages: 105
The Pharmaceutical Parallel Trade Outlook: Challenges to pharmaceutical companies across Europe and the US, analyzes parallel trade market dynamics, reviews the latest regulatory and pricing controls in the EU and US, and assesses the drivers and resistors of parallel trade in 2004. The two main areas this report focuses on are; the implications for pharmaceutical companies of the expansion of the EU in May 2004 and the fear of parallel trade taking greater hold on the US pharmaceutical market. The former is a major development since it will open up several more low-priced countries as sources of parallel traded drugs. The latter has made some big pharmaceutical companies, like Pfizer and GSK, limit the volume of drugs they supply to Canada, as parallel trade between the two countries is now legal. In addition, it's becoming increasingly apparent that price differences alone are insufficient to drive PT. Other driving forces include supportive regulatory frameworks, patient populations and reduced transport costs.
Region: Europe, US
Customers who bought this item also bought
Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, Initiatives and Insights for Supply Chain Integrity
How to React to Parallel Trade
Parallel Trade in Europe and the US: The Challenges Facing Pharma
Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006: Market Insights and Trends in a Primary Import Destination
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
European Patient Safety and Parallel Pharmaceutical Trade - A Potential Public Health Disaster?
Online Pharmacies: Current and Prospective Impact on Pharmaceutical Sales in Europe and the US
Parallel Optics on the Move
The Outlook for Pharmaceuticals in Western Europe
The Revival and Emergence of Parallel Optics
The Outlook for Pharmaceuticals in Central & Eastern Europe to 2013
The Outlook for Pharmaceuticals in Northern Europe to 2013
|
|
|
|
